Parabilis Medicines, Inc. (PBLS) vs Xenon Pharmaceuticals Inc. (XENE)
A side-by-side comparison of Parabilis Medicines, Inc. and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PBLS
Parabilis Medicines, Inc.
$28.55HealthcareDelayed quote: Oct 6, 2026, 1:40 PM EDT
XENE
Xenon Pharmaceuticals Inc.
$35.96HealthcareDelayed quote: Oct 6, 2026, 1:35 PM EDT
Total return — PBLS vs XENE
growth of $100 · dividends reinvested · last 1yPBLS +47.7% (+47.7%/yr)XENE -29.1% (-29.1%/yr)PBLS compounded faster over this window
PBLS XENE
PBLS vs XENE: by the numbers
- •XENE is the larger company ($3.48B vs $3.33B market cap).
- •Both run net losses; PBLS's is the smaller (0.00% vs -4612.13% net margin).
Metrics side by side
Valuation
| Metric | PBLS | XENE |
|---|---|---|
| P/B ratio | 3.18 | 2.80 |
Profitability
| Metric | PBLS | XENE |
|---|---|---|
| Gross margin | 0.00% | 66.09% |
| Operating margin | 0.00% | -4974.27% |
| Net margin | 0.00% | -4612.13% |
| ROE | N/A | -32.94% |
| ROIC | -409.85% | -35.27% |
Growth (annualized)
| Metric | PBLS | XENE |
|---|---|---|
| Total return CAGR (5Y) | N/A | 4.61% |
Go deeper
Dig into the metrics
Parabilis Medicines ROEXenon Pharmaceuticals ROEParabilis Medicines operating marginXenon Pharmaceuticals operating marginParabilis Medicines revenue growthXenon Pharmaceuticals revenue growthParabilis Medicines free cash flowXenon Pharmaceuticals free cash flow
Parabilis Medicines & Xenon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.